Computational Deconvolution of Cell Type-Specific Gene Expression in COPD and IPF Lungs Reveals Disease Severity Associations

Min Hyung Ryu[1,3], Jeong H. Yun[1,2,3], Kangjin Kim[1,3], Michele Gentili[1,3], Auyon Ghosh[4], Frank Sciurba[5], Lucas Barwick[6], Andrew Limper[7], Gerard Criner[8], Kevin K. Brown[9], Robert Wise[10], Fernando J. Martinez[11], Kevin R. Flaherty[12], Michael H. Cho[1,2,3], Peter J. Castaldi[1,3,13], Dawn L. DeMeo[1,2,3], Edwin K. Silverman[1,2,3], Craig P. Hersh[1,2,3,#], Jarrett D. Morrow[1,3,#]

[1] Channing Division of Network Medicine, and [2] Division of Pulmonary and Critical Care Medicine, [13] Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts

[3] Harvard Medical School, Boston, Massachusetts.

[4] Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York

[5] Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

[6] Emmes, Frederick, Maryland

[7] Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

[8] Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania

[9] Department of Medicine, National Jewish Health, Denver, Colorado

[10] Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland

[11] Department of Medicine, Weill Cornell Medical College, NYPresbyterian Hospital, New

York, New York

[12] Division of Pulmonary and Critical Care Medicine, University of Michigan Health System,

Ann Arbor, Michigan

co-senior authors.

Corresponding Author:

Craig P Hersh, MD, MPH

Channing Division of Network Medicine,

Brigham and Women's Hospital

181 Longwood Ave. Boston, MA 02115

craig.hersh@channing.harvard.edu

Phone 617-525-0729

Fax 617-525-0958

ABSTRACT

Total word count: 349

Rationale: Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis

(IPF) are debilitating diseases associated with divergent histopathological changes in the lungs.

At present, due to cost and technical limitations, profiling cell types is not practical in large

epidemiology cohorts (n>1000). Here, we used computational deconvolution to identify cell

types in COPD and IPF lungs whose abundances and cell type-specific gene expression are

associated with disease diagnosis and severity.

Methods: We analyzed lung tissue RNA-seq data from 1026 subjects (COPD, n=465; IPF,

n=213; control, n=348) from the Lung Tissue Research Consortium. We performed RNA-seq

deconvolution, querying thirty-eight discrete cell-type varieties in the lungs. We tested whether

deconvoluted cell-type abundance and cell type-specific gene expression were associated with

disease severity.

Results: The abundance score of twenty cell types significantly differed between IPF and

control lungs. In IPF subjects, eleven and nine cell types were significantly associated with

forced vital capacity (FVC) and diffusing capacity for carbon monoxide (D_LCO), respectively.

Aberrant basaloid cells, a rare cells found in fibrotic lungs, were associated with worse FVC and

D_LCO in IPF subjects, indicating that this aberrant epithelial population increased with disease

severity. Alveolar type 1 and vascular endothelial (VE) capillary A were decreased in COPD

lungs compared to controls. An increase in macrophages and classical monocytes was associated

with lower D_LCO in IPF and COPD subjects. In both diseases, lower non-classical monocytes

and VE capillary A cells were associated with increased disease severity. Alveolar type 2 cells

and alveolar macrophages had the highest number of genes with cell type-specific differential

expression by disease severity in COPD and IPF. In IPF, genes implicated in the pathogenesis of

IPF, such as matrix metallopeptidase 7, growth differentiation factor 15, and eph receptor B2,

were associated with disease severity in a cell type-specific manner.

Conclusion: Utilization of RNA-seq deconvolution enabled us to pinpoint cell types present in

the lungs that are associated with the severity of COPD and IPF. This knowledge offers valuable

insight into the alterations within tissues in more advanced illness, ultimately providing a better

understanding of the underlying pathological processes that drive disease progression.

Keywords

Chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, RNA sequencing,

computational deconvolution, lung function tests, cell type-specific gene expression.

List of Abbreviations

ATI, alveolar type 1 pneumocytes; ATII, alveolar type 2 pneumocytes; COPD, chronic

obstructive pulmonary disease; DLCO, diffusing capacity for carbon monoxide; FACS,

fluorescence-activated cell sorting; FDR, false discovery rate; FEV1, forced expiratory volume

in one second; FVC, forced vital capacity; IIPs, idiopathic interstitial pneumonias; ILC A, type A

innate lymphoid cells; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; IQR,

interquartile range; LTRC, Lung Tissue Research Consortium; PPI, protein-protein interaction;

RNA-seq, RNA sequencing; SMC, smooth muscle cells; SMC, smooth muscle cells; TGF-β,

transforming growth factor beta; VE Capillary A, vascular endothelial - aerocyte capillary; VE

Capillary B, vascular endothelial - general capillary; VE Venous, vascular endothelial venous

cells; cMonocyte, classical monocytes; ncMonocyte, non-classical monocytes; pDC,

plasmacytoid dendritic cells, and; scRNA-seq, single-cell RNA sequencing

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are debilitating chronic diseases of the lungs with progressive and complex pathobiology [1,2]. COPD is characterized by airflow limitation, chronic airway inflammation, and lung parenchymal destruction [1]. IPF is characterized by cellular proliferation, interstitial inflammation, and fibrosis [2]. COPD and IPF are both related to long-term inhalation of noxious agents (e.g. tobacco smoking) and manifest in older adults as accelerated lung aging [3]. As such, both diseases are associated with significant morbidity, mortality, and a high economic burden to our society [4,5]. Therefore, there is an urgent need for disease prevention and improved treatments.

Genetics plays a role in predisposition to both diseases; eighty-two and nineteen loci have been associated with the risk of developing COPD or IPF, respectively [6,7]. COPD and IPF risk loci are enriched for pathways important in regulating cellular functions. For example, COPD risk loci are enriched for pathways regulating extracellular-matrix, cell-matrix adhesion, histone deacetylase binding, the Wnt-receptor signaling pathway, SMAD binding, and the MAPK cascade [6]. Similarly, IPF risk loci are enriched for pathways related to host defense, cell-cell adhesion, spindle assembly, transforming growth factor beta (TGF-β) signaling regulation, and telomere maintenance [8]. Furthermore, genetic factors are postulated to impact disease susceptibility in a cell type-specific and context specific manner. Therefore, improved molecular characterization of cells in the diseased lungs may provide insight into understanding disease pathobiology, paving the path to new therapeutics.

Investigating the molecular and cellular aspects of pathological lungs in the context of these diseases holds great promise for developing preventative and treatment strategies. In particular,

single-cell RNA sequencing (scRNA-seq) has been used in COPD and IPF patients to search for putative disease-causing cell types. For example, scRNA-seq analysis of IPF lungs has identified aberrant basaloid cells, a rare, disease-enriched cell type [9]. In COPD lungs, scRNA-seq has identified a high metallothionein-expressing macrophage subpopulation enriched in advanced COPD and altered bioenergetics and cellular stress tolerance in an alveolar type 2 pneumocyte (ATII) subpopulation [10]. A recent multi-omic single-cell analysis revealed a CD8$^+$ T cell subpopulation (KLRG1+TEMRA cells) to be enriched in COPD lung tissue [11]. However, the number of subjects included in these prior studies was modest, limiting the generalization to a larger patient population.

Due to the cost and technical limitations, performing scRNA-seq or tissue dissection experiments combined with fluorescence-activated cell sorting are yet to be practical in large epidemiology cohorts (n>1000). Moreover, the impact of tissue dissociation on gene expression in fluorescence-activated cell sorting (FACS) and scRNA-seq protocols remains poorly understood. Given that COPD and IPF are heterogeneous diseases, molecular studies encompassing a wide range of subjects with cell type-specific resolution are needed to unravel the complex interplay of cells in disease pathophysiology. To this end, large-scale clinical and genomic data in population cohorts may be leveraged to advance our search for cellular drivers of COPD and IPF pathogenesis.

In the present study, we performed computational deconvolution with bulk lung homogenate RNA-seq data from 1,026 subjects in the Lung Tissue Research Consortium (LTRC). By leveraging the large-scale omics data, we tested the hypothesis that there are specific cell types whose abundance and cell type-specific gene expression are associated with disease severity in COPD and IPF subjects.

METHODS

Study participants

Research subjects undergoing clinically indicated thoracic surgery were recruited to participate in the LTRC, as previously described [12]. The participating centers' Institutional Review Boards approved the study, and all subjects provided written informed consent.

COPD subjects included in this analysis had forced expiratory volume in one second (FEV_1) to forced vital capacity (FVC) ratio <0.70 and FEV_1 % predicted <80%. Spirometric severity was characterized by Global Initiative for Chronic Obstructive Lung Disease spirometry grades 2-4. COPD subjects had either pathological emphysema and no alternative pathological diagnosis (interstitial lung disease (ILD), idiopathic interstitial pneumonias (IIPs), sarcoidosis, constrictive bronchiolitis, cellular hypersensitivity pneumonitis, diffuse alveolar damage, or eosinophilic granuloma). Any individual meeting the physiological diagnostic criteria for COPD but with a clinical diagnosis of IPF or sarcoidosis was excluded from the COPD group.

IPF subjects had a clinical diagnosis of IPF based on the site's multidisciplinary diagnostic process of all available data instituted at each participating institution. Control subjects had normal spirometry with no pathologic diagnosis of ILD/IIPs, sarcoidosis, constrictive bronchiolitis, cellular hypersensitivity pneumonitis, diffuse alveolar damage, or eosinophilic granuloma.

Computational deconvolution

Computational deconvolution was performed using CIBERSORTx (available at https://cibersortx.stanford.edu/) [13]. The docker image obtained from CIBERSORTx website

was used with the Podman container image management engine on the Channing Division of

Network Medicine GPU computing cluster. This provided computational efficiency beyond what

was available through the CIBERSORTx web interface.

We used LTRC TOPMed Harmonized phenotype data set dated November 30, 2022 and freeze 1

LTRC gene expression data set. Data are available on the NCBI database of Genotypes and

Phenotypes (dbGaP), accession phs001662 (LTRC). LTRC RNA-seq data from TOPMed

(https://topmed.nhlbi.nih.gov) are available through dbGaP. For the count matrix generation,

isoform-level expression quantification was generated with Salmon (v1.3.0) pseudoalignment to

GENCODE release 37 transcriptome and summarized to gene-level counts using tximeta

(v1.8.5). For salmon alignment, seq_bias_correct and gc_bias_correct were set to TRUE.

Deconvolution was performed on the entire LTRC dataset that passed RNAseq QC (n=1,555),

irrespective of whether the subject was included in our final analysis. Batch effects (library

preparation batch) were removed using Combat_seq in the sva R package, and the matrix was

cpm normalized after batch effect removal. Genes that had cpm >1 in at least 20% of the LTRC

dataset and had assigned HUGO Gene Nomenclature Committee symbols were used in the

deconvolution.

In total, 23,097 genes were included in the deconvolution after the batch effect removal and

filtering steps. A custom signature matrix from a reference scRNA-seq was generated using

CIBERSORTx. The signature matrix is a specialized expression matrix of cell type-specific

"barcode" genes which provides a reference atlas of known cellular signatures for the

deconvolution procedure. For this process, the CIBERSORTx algorithm used scRNA-seq data

on 31,943 lung cells from 44 ever-smokers: six control, seventeen COPD, and twenty-one IPF

subjects)[9,10]. Of the 23,097 genes in the LTRC dataset, 19,655 were also in the scRNA-seq

dataset (42,406 features across 161,067 cells in the qc'ed dataset); these genes were used to train

the CIBERSORTx algorithm. The CIBERSORTx signature matrix we generated is attached as a

supplementary file. Thirty-eight discrete cell varieties were queried in the deconvolution; cells

were labeled as per Adams et al (Supplemental Table E1) [9]. We chose to use this dataset for

two main reasons: 1.) the dataset included a wide range of control, COPD, and IPF subjects. 2.)

the dataset included disease-specific cell types such as aberrant basaloid cells. Moreover, the cell

annotations for the scRNA-seq were shown to be consistent with automated annotation drawn

from multiple cell type definition databases such as the Human Primary Cell Atlas and Blue

ENCODE databases, as previously reported [9].

For the imputation of cell fraction, we used CIBERSORTx in fraction mode with single-cell

mode set to TRUE and rmbatchSmode set to FALSE; i.e., batch correction and quantile

normalization by the CIBERSORTx algorithm were disabled. Proportions were calculated for

each sample with all the cell types proportions added up to 1. For deriving abundance scores for

cell types, the computation was performed on the CIBERSORTx web interface as this specific

function is disabled by the algorithm provided by the authors inside the docker image.

CIBERSORTx estimates the relative fraction of each cell type included in the signature matrix,

such that the sum of all fractions is equal to 1 for a given bulk RNA-seq sample. Therefore, the

number of cell types included in the signature matrix may impact the relative fraction of each

cell type. To overcome this issue, we used CIBERSORTx absolute mode where the absolute

abundance score was estimated by the median expression level of all genes in the signature

matrix (matrix generated using the reference scRNA-seq matrix) divided by the median

expression level of all genes in the sample mixture (LTRC gene expression) [14,15]. This

approach allows relative abundance comparisons across samples and cell types.

Cell type-specific gene expression matrices were generated using CIBERSORTx high-resolution

mode using the docker image and used in the subsequent analyses.

Cell type-specific differential gene expression analysis

We performed differential gene expression analysis in cell type-specific gene expression

matrices to find out which genes, even after removing the cellular abundance effects, were

differentially expressed between case and controls. Using cell type-specific gene expression

matrices (gene-by-sample matrices for each cell type) generated from CIBERSORTx, we

performed differential gene expression analysis using limma [16]. Cell type-specific differential

gene expression was $\log_2$-transformed, and we included only the genes with varying levels in our

analysis (a built-in function of CIBERSORTx). We tested the association between cell type-

specific gene expression and disease severity separately in the COPD and IPF groups. In COPD

subjects, disease severity was measured by lung function tests including forced expiratory

volume in 1 second (FEV_1) and diffusing capacity of the lungs for carbon monoxide as a percent

predicted (D_LCO %). In IPF subjects, disease severity was measured by forced vital capacity

(FVC) and D_LCO %. Linear models were adjusted for age, sex, height, ever smoking, and

lifetime smoking intensity (in pack-years). Multiple testing correction was performed by the

Benjamini-Hochberg procedure. Significance was determined at a false discovery rate (FDR) of

5%.

Functional enrichment analysis

We performed functional enrichment analysis using the STRING database version 12.0

(https://string-db.org) [17]. The reason for using STRING was to use a complementary method

based on publicly available dataset to explore the functional consequences of differentially

expressed genes. Alongside the protein-protein interaction, we also report gene set enrichment

results performed using cell type-specific gene expression data which is part of the STRING

interactive online platform.

Using the STRING interactive online platform, we queried active interaction sources and

obtained confidence value in functional protein-protein interactions for protein network

construction. We excluded any protein-protein interaction source that was based on text mining

to reduce false positive signals. Active interaction sources include experiments, databases, co-

expression, neighborhood, gene fusion, and co-occurrence. The list of genes used in the

functional enrichment analysis are included in the Supplemental Table E2 and E3.

RESULTS

Subjects

465 subjects met the case criteria for COPD, 213 subjects met the case criteria for IPF, and 348

subjects met the control criteria. Demographic and clinical characteristics of the 1,026 subjects

included in our analysis are shown in Table 1. Notably, IPF subjects were predominantly male

(70%). The cohort included 90% of self-identified white subjects. COPD subjects were

predominantly smokers (95.2% have ever smoked) and IPF and control subjects were 65.3% and

67.8% ever smokers, respectively.

Cellular composition differences among COPD, IPF, and controls

Of the thirty-eight cell types queried in the deconvolution, twenty-seven cell types were detected

in at least 10% of samples. Of these, there were nineteen cell types whose median proportion was

greater than 1% in any one of the groups, as shown in Figure 1.

We compared the cell abundance score between COPD, IPF, and control subjects, adjusting for

age, sex, height, ever smoking, and smoking pack-years. Figure 1 summarizes cell types whose

abundance scores were significantly different (FDR<0.05) between COPD and control subjects

and between IPF and control subjects, respectively. VE Capillary A and ATI were lower in

COPD tissue compared to controls. Nine cell types were decreased and eleven were increased in

IPF compared to controls.

Associations between cell-type abundance and disease severity in COPD and IPF lungs

Next, we identified cell types whose abundance scores in COPD and IPF lungs were associated

with disease severity measured by FEV_1 (COPD), FVC (IPF), and D_LCO (COPD and IPF). In

COPD subjects, there were two and six cell types that were significantly associated with FEV_1

and D_LCO, respectively (Table 2). In IPF subjects, there were eleven and nine cell types that

were significantly associated with FVC and D_LCO, respectively (Table 2). Decreases in the

abundances of type A capillary vascular endothelial cells and non-classical monocytes were

associated with worse disease severity in both COPD and IPF subjects. In IPF, aberrant basaloid

cells showed the strongest association with both FVC and D_LCO. In fact, we performed

additional analysis testing the association between cell abundance score and GAP index [18], a

mortality predictive score based on gender (G), age (A), and physiological measures (P; FVC,

and D_LCO) in IPF, and found that aberrant basaloid cells had one of the strongest associations

with the index (Supplemental Table E4).

Associations between cell type-specific gene expression and disease severity in COPD and IPF lungs

We estimated cell type-specific gene expression for cell types whose median proportion was greater than 1%: ATII, Alveolar Macrophage, SMC, Fibroblast, ATI, Myofibroblast, VE Capillary B, B Plasma, VE Capillary A, ILC A, VE Venous, Pericyte, and T Cytotoxic. Table 3 summarizes the number of differentially expressed genes in COPD and IPF. Overall, there were more differentially expressed genes (FDR<0.05) in IPF lungs than in COPD lungs. ATII cells and alveolar macrophages were two cell types with the greatest number of genes with cell type-specific differential gene expression associated with disease severity in both diseases. Aberrant basaloid cells, despite being estimated to represent only 1.3 % (IQR: 0-3.5 %) of cell proportion in IPF subjects, had the second largest number of cell type-specific genes whose expression was positively associated with IPF severity.

Next, we tested the association between cell type-specific gene expression and disease severity in COPD and IPF subjects. We included all cell types whose median proportion was greater than 1% in each disease group. In COPD subjects, cell types tested were Alveolar Macrophage, ATI, ATII, B Plasma, Fibroblast, ILC A, Myofibroblast, Pericyte, SMC, T Cytotoxic, VE Capillary A, VE Capillary B, and VE Venous. In IPF subjects, cell types tested included Aberrant Basaloid, Alveolar Macrophage, ATI, ATII, B Plasma, Fibroblast, ILC A, Myofibroblast, Pericyte, SMC, T Cytotoxic, VE Capillary B, and VE Venous. Figure 2 (and Figure E2) shows the number of genes with cell type-specific expression associated with lung function measures in COPD and IPF subjects. We also provide a list of all cell type-specific gene expression associations with disease severity in IPF and COPD (Supplemental Table E5 and 6). Figure 2 also shows the number of genes with cell that overlap between the two different measures of disease severity.

Supplemental Tables E7 and E8 summarize the number of significant cell type-specific gene

expressions associated with disease severity in COPD and IPF, respectively. Of note, besides the

ATII cells, which were the most abundant cell types in the samples estimated using RNA-seq

deconvolution, alveolar macrophages in COPD and aberrant basaloid cells had the highest

number of genes associated with disease severity in both COPD and IPF. Hence, we chose these

two cell types to perform functional enrichment analyses and highlight their upregulated

function.

Functional enrichment analysis of genes associated with COPD severity in alveolar

macrophages

We performed functional enrichment analysis using the list of genes whose expression levels in

alveolar macrophages were positively associated with COPD severity as measured by FEV_1 and

D_LCO. We queried all matched proteins encoded by the 77 genes identified in this cell type-

specific differential gene expression analysis. In the protein-protein interaction (PPI) network

analysis in the STRING database, we found significant functional enrichment with 144 edges

(expected number of edges 60; PPI enrichment p-value $<1x10^{-16}$). Figure 3 shows the PPI

network for proteins encoded by the alveolar macrophage gene expression that is positively

associated with COPD severity. The result of the functional enrichment analysis is included in

the online Supplement Table E8. The most significantly enriched term was from the Reactome

database for Eukaryotic Translation Elongation (Reactome term HSA-156842: FDR = 1.25 x 10$^-$

^{11}).

Functional enrichment analysis of genes associated with IPF severity in aberrant basaloid

cells

We performed functional enrichment analysis using the list of genes whose expression levels in

aberrant basaloid cells were positively associated with IPF severity as measured by FVC and

D_LCO. We queried all matched proteins encoded by the 185 genes identified in the cell type-

specific differential gene expression analysis. We found significant functional enrichment with

123 edges (expected number of edges 53; PPI enrichment p-value = 2.22×10^{-16}). Figure 4 shows

the PPI network for proteins encoded by the aberrant basaloid genes positively associated with

IPF severity. The result of the functional enrichment analysis is included in the Online

Supplement Table E9. Formation of the cornified envelope (STRING Cluster ID CL34114; FDR

= 5.85×10^{-14}) was indicated as the top most significant functional enrichment term.

DISCUSSION

We report the results of a computational tissue profiling analysis of bulk lung RNA-seq data

from 1,026 subjects in the LTRC. We report the cellular composition and cell type-specific gene

expression in lung tissue associated with disease severity in COPD and IPF subjects, extending

the single-cell experiment discoveries from a modest sample size (<100 subjects) to a large

population cohort (>1000 subjects). We trained a well-established and widely implemented

computational RNA-seq deconvolution algorithm, CIBERSORTx [13,19,20], using publicly

available scRNA-seq data from control, COPD, and IPF subjects [9].

We found that IPF lung tissues showed the most divergence from control lungs in cellular

composition, with eighteen cell types whose abundance score was different from the controls,

adjusting for covariates. Our results showed in a large IPF sample the association of aberrant

basaloid cells and their expression with IPF and IPF severity; the association with IPF severity

has not been previously reported. We also found that abundances of eight cell types—

ncMonocyte, Aberrant Basaloid, Macrophage, cMonocyte, T Cytotoxic, ATII, Alveolar

Macrophage, and VE Capillary A—were associated with disease severity in the IPF subjects.

Structural cells such ATII, aberrant basaloid cells, myofibroblasts, and fibroblasts were among

the cell types with the most number of genes associated with IPF severity. Notably, we found

that aberrant basaloid cells were enriched in IPF lungs, and that the abundance of this disease-

enriched cell type increased as the disease severity increased. It is notable that aberrant basaloid

proportions remained below 1% in COPD.

In aberrant basaloid cells, expression levels of matrix metallopeptidase 7 (*MMP7*), growth

differentiation factor 15 (*GDF15*), and eph receptor B2 (*EPHB2*), were negatively associated

with FVC or $D_L CO$. In other words, the expression of these genes increased in more severe

disease. These genes and the protein they encode have been implicated in the pathogenesis of

IPF [21–24]. Our data supports the notion that GDF15 may be circulating biomarker reflective of

aberrant basaloid cells in the airway epithelium [23]. We also found that *EPHB2* level in

myofibroblasts was positively associated with IPF severity, extending the previous scRNA-seq

finding that demonstrated increase level of *EPHB2* in IPF subjects compared to controls [9].

The functional enrichment analysis showed that the formation of the cornified envelope and

keratinization were functionally enriched in aberrant basaloid cells with increasing severity of

IPF. The cornified cell envelope is a highly insoluble and extremely tough structure that forms

under the epithelium to help the epithelium defend against reactive oxygen species [25]. This

may result from and/or be a contributing factor to the tissue fibrosis in IPF; however, alteration

in this cellular function has not been implicated in IPF previously. Therefore, this result will

require further validation at the protein level. In addition to these functions, the protein

interaction network analysis also highlighted the increased expression of matrix metalloproteases

such as *MMP7*, *MMP10*, and *MMP1*, along with their functionally associated genes such as

lipopolysaccharide binding protein (*LBP*), lipocalin 2 (*LCN2*), and transcobalamin1 (*TCN1*), in

aberrant basaloid cells with increased disease severity. These results suggest that increased

abundance of aberrant basaloid cells and their gene expression of cellular processes involved in

aberrant barrier formation and extracellular matrix modification is associated with IPF severity.

We also showed that cellular composition is different between COPD and controls and that there

were several cell types whose abundance was associated with COPD severity. There was a

significant decrease in alveolar type 1 cells and capillary type A vascular endothelial cells in

COPD lungs compared to controls. Capillary type A vascular endothelial cells were also

negatively associated with increasing disease severity as measured by FEV_1 and D_LCO. This

observation provides additional evidence linking endothelial injury to COPD and extends earlier

findings that identified injury to pulmonary vessels in lung tissue from COPD patients [26].

Beyond the pulmonary vasculature, the abundance of macrophage, ncMonocyte, and cMonocyte

were associated with D_LCO, but only ncMonocytes abundance was significantly associated with

FEV_1.

Monocytes and macrophages play an important role in pulmonary host defenses through their

phagocytic activities and regulation of innate and adaptive immunity. The circulating monocyte

pool and macrophages in tissue are composed of multiple subsets, each with a specialized

function. Animal models and human *ex vivo* experiments have demonstrated the dysregulated

functions of macrophage populations in COPD lungs [27]. Extensive molecular characterizations

of immune cells in COPD, particularly the lung macrophage populations, have been conducted

using flow cytometry and other low-throughput molecular techniques [28–30]. However, due to

the practicality of needing fresh samples and the experimental cost, tissue and immune profiling

studies have been limited in terms of sample sizes (typically <100 subjects) and the small

number of molecular targets. Recently, scRNA-seq studies with more molecular targets have

been conducted and highlighted immunological dysregulation of monocytes and macrophages in

COPD [9,10,31,32]. However, the number of COPD donors was small in these studies, and there

was limited information on the disease phenotypes, which limited the ability to test for

associations with disease severity, clinical outcomes, and pathological changes. Our

computational tissue profiling in a large-scale cohort builds on this important body of work and

extends the findings from scRNA-seq to an epidemiological cohort.

Given the important role alveolar macrophages play in COPD pathogenesis, we focused on this

cell type for functional enrichment analysis, which highlighted that increased disease severity

was associated with increased mRNA encoding for proteins involved in translation and energy

metabolism. This finding agrees with previous studies that macrophage metabolic function is

associated with COPD and supports the notion that metabolomic reprogramming of lung

macrophages is important in the pathogenesis of COPD [33,34]. We provide the list of cell type-

specific genes associated with COPD and IPF severity (Supplemental Table E5 and E6) for the

community to explore using the cell type-specific functional enrichment using tools such as

STRING database (https://string-db.org/) for other cell types.

There are some limitations of our study. First, RNA-seq based deconvolution methods are more

suited for analysis of highly abundant cell types (cell types with frequency >1%) [13,19]. It is

also influenced by the size of the cell type-specific transcriptome. This makes rare cell types with

small transcriptomes challenging to study using the deconvolution approach. To overcome this

issue, future studies may combine RNA-seq deconvolution with results based on other omics

(e.g., DNA methylation-based deconvolution). Also, careful enrichment of a cell type by FACS

sorting may be required to study rarer cell populations. Second, bulk tissue analysis is limited in

spatial resolution. This limits the understanding of the spatial distribution and interaction of cells

in the diseased lungs. Nevertheless, our study informs which cell types may be the better

candidates to be the focus of future spatial transcriptomic investigations. Finally, the study was

limited to a population of predominantly white subjects with access to U.S. academic medical

centers. This may limit the generalizability and calls for future efforts to include subjects from

multi-ethnic and multi-national backgrounds.

CONCLUSION

In conclusion, we present here the cellular composition changes and cell type-specific gene

expression associated with disease severity in COPD and IPF lungs. We document the cell types

whose estimated abundance is associated with the severity of disease in COPD or IPF. We

highlight two cell types—alveolar macrophages in COPD and aberrant basaloid cells in IPF—

whose cell type-specific gene expressions were associated with clinical measures of disease

severity. We also highlight the cell type-specific functional enrichment pointing to the altered

cellular functions associated with disease severity. Using computational deconvolution, this

study extends single-cell experimental discoveries from a modest sample size to a large

population cohort and contributes to our understanding of tissue heterogeneity in COPD and IPF

pathobiology. This knowledge offers insight into the alterations within lung tissue in advanced

illness, providing a better understanding of the underlying pathological processes that drive

disease progression.

DECLARATIONS

Ethics approval and consent to participate

The participating centers' Institutional Review Boards approved the study, and all subjects

provided written informed consent.

Consent for publication

Not applicable.

Availability of data and materials

Data are available on the NCBI database of Genotypes and Phenotypes (dbGaP), accession

phs001662 (LTRC). LTRC RNA-seq data from TOPMed (https://topmed.nhlbi.nih.gov) are

available through dbGaP. The analysis results and code can be obtained by contacting the

corresponding author with a reasonable request.

Competing Interests

Dr. Hersh reports grant support from Bayer, Boehringer-Ingelheim, and Vertex, and consulting

fees from Chiesi, Sanofi, and Takeda, unrelated to this manuscript. Dr. Silverman reports grant

support from Bayer and Northpond Laboratories. Dr. Cho reports grant support from Bayer.

Dr. DeMeo reports grant support from Bayer and Alpha-1 Foundation. Dr. Castaldi reports grant

support from Bayer, Sanofi and consulting fees from Verona Pharmaceuticals. Dr. Yun reports

grant support from Bayer and consulting fees from Bridge Biotherapeutics, and travel

reimbursement from the Korean Academy of Tuberculosis and Respiratory Disease unrelated to

this manuscript. Dr. Flaherty reports grant funding from Boehringer Ingelheim unrelated to this

manuscript. Dr. Martinez reports grant supports from NHLBI, AstraZeneca, Chiesi, Boehringer-

Ingelheim, GalaxoSmithCline, Novartis, Polarean, Sanofi/Regeneron, Sunovion, and TEVA

Pharmaceuticals. Dr. Martinez reports receiving consulting fee from AstraZeneca, Boehringer-

Ingelheim and Bristol Myers Squibb. Dr. Wise reports receiving consulting fees from

Boehringer-Ingelheim, AstraZenica, Abb-Vie, and Galderma.

Funding

Present work was supported by grants from NHLBI (R01HL166231, P01HL114501,

R01HL133135, and X01HL139404), K25 HL136846, K08 HL146972, Alpha-1 Foundation

Research Grant, and TOPMed Fellowship. MHC was supported by R01HL162813,

R01HL153248, R01HL14.

Author contributions

Concept and design: MHR, CPH, and JDM; data collection: JHY, FS, LB, AL, GC, KB, RW,

FM, KF, MHC, PJC, DLD, EKS, CPH, and JDM; statistical support: MHR, KJK, MG, CPH,

JDM; data analysis: MHR, JHY, KJK, MG, AG, and JDM; manuscript writing - draft: MHR,

CPH, and JDM; manuscript writing - edit: all authors; funding: PJC, EKS, and CPH. All authors

read and approved the final manuscript.

Acknowledgements

NHLBI TOPMed: Lung Tissue Research Consortium Molecular data from the Trans-Omics in

Precision Medicine (TOPMed) program was supported by the National Heart, Lung, and Blood

Institute (NHLBI). RNASeq for "NHLBI TOPMed: Lung Tissue Research Consortium"

(phs001662) was performed at the Northwest Genomics Center (HHSN268201600032I). Core

support including centralized genomic read mapping and genotype calling, along with variant

quality metrics and filtering were provided by the TOPMed Informatics Research Center

(3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype

harmonization, data management, sample-identity QC, and general program coordination were

provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract

HHSN268201800001I). We gratefully acknowledge the studies and participants who provided

biological samples and data for TOPMed.

TABLES

Table 1: LTRC subject demographics and lung function tests

	Control	COPD	IPF
n	348	465	213
Age (mean (SD))	61.51 (12.53)	63.35 (9.18)	63.55 (8.37)
Sex = Female sex (%)	211 (60.6)	210 (45.2)	64 (30.0)
Race (%)			
White	314 (90.2)	423 (91.0)	191 (89.7)
Asian	0 (0.0)	0 (0.0)	4 (1.9)
Black	22 (6.3)	29 (6.2)	8 (3.8)
Hispanic	10 (2.9)	9 (1.9)	4 (1.9)
Other race	2 (0.6)	4 (0.9)	6 (2.8)
BMI (mean (SD))	28.95 (5.97)	26.30 (5.22)	29.80 (5.44)
Ever Smoking (%)	215 (67.8)	415 (95.2)	128 (65.3)
Pack years of smoking (mean (SD))	20.12 (27.32)	47.16 (31.73)	18.84 (24.18)
FEV1/FVC (mean (SD))	0.77 (0.06)	0.45 (0.15)	0.83 (0.07)
FEV1 pp (mean (SD))	95.87 (12.61)	41.72 (20.27)	65.91 (19.06)
FVC pp (mean (SD))	96.09 (12.69)	68.36 (18.50)	60.28 (17.75)
DLCO % (mean (SD))	73.22 (15.44)	42.92 (18.87)	38.04 (19.59)

Abbreviations: COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary

fibrosis; SD, standard deviation; BMI, body mass index; FEV_1, forced expiratory volume in 1s;

FVC, forced vital capacity; DLCO, diffusing capacity of the lungs for carbon monoxide as a

percent predicted.

Table 2: Cell-type transcriptome abundance score associated with disease severity in COPD and
IPF.

Disease	Outcome	Cell type	Beta	95% CI	Adjusted p value
COPD	FEV_1	VE Capillary A	0.11	0.06,0.16	0.001
COPD	FEV_1	ncMonocyte	0.09	0.03,0.14	0.02
COPD	D_LCO	ATI	4.79	2.99,6.59	<0.001
COPD	D_LCO	Macrophage	-4.75	-7.02,-2.49	<0.001
COPD	D_LCO	ncMonocyte	3.71	1.94,5.49	<0.001
COPD	D_LCO	VE Capillary A	3.69	1.95,5.44	<0.001
COPD	D_LCO	cMonocyte	-3.16	-5.47,-0.86	0.031
COPD	D_LCO	ILC A	2.72	0.93,4.51	0.016
IPF	FVC	ncMonocyte	0.31	0.21,0.4	<0.001
IPF	FVC	Aberrant Basaloid	-0.24	-0.34,-0.14	<0.001
IPF	FVC	Macrophage	-0.20	-0.31,-0.1	0.001
IPF	FVC	cMonocyte	-0.19	-0.29,-0.09	0.001
IPF	FVC	T Cytotoxic	0.19	0.09,0.29	0.002
IPF	FVC	ATII	0.16	0.06,0.27	0.007
IPF	FVC	VE Venous	-0.16	-0.27,-0.06	0.012
IPF	FVC	Alveolar Macrophage	0.15	0.05,0.25	0.016
IPF	FVC	VE Capillary A	0.15	0.05,0.26	0.016
IPF	FVC	T	-0.14	-0.24,-0.03	0.029
IPF	FVC	pDC	-0.12	-0.23,-0.02	0.046
IPF	D_LCO	Aberrant Basaloid	-6.42	-9.25,-3.58	<0.001
IPF	D_LCO	Alveolar Macrophage	6.08	3.19,8.97	0.001
IPF	D_LCO	ATII	5.65	2.8,8.51	0.001
IPF	D_LCO	T Cytotoxic	5.07	2.04,8.1	0.006
IPF	D_LCO	VE Capillary A	5.06	2.1,8.03	0.006
IPF	D_LCO	ncMonocyte	4.79	1.89,7.69	0.006
IPF	D_LCO	Macrophage	-4.64	-7.64,-1.65	0.01
IPF	D_LCO	cMonocyte	-4.34	-7.53,-1.15	0.023
IPF	D_LCO	T Regulatory	3.92	1.06,6.77	0.023

Statistical comparison was tested using linear regression adjusting for age, sex, height, ever

smoking and total pack-year. Beta was estimated using absolute value of outcome measures and

are estimated per one standard deviation change in CIBERSORTx absolute abundance score.

Pre-bronchodilator FEV_1 and DLCO percent predicted were used. Abbreviations: COPD, chronic

obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; CI, confidence interval;

FEV_1, forced expiratory volume in 1s; FVC, forced vital capacity; DLCO, diffusing capacity of

the lungs for carbon monoxide as a percent predicted; VE Capillary A, vascular endothelial -

aerocyte capillary; ncMonocyte, non-classical monocytes; cMonocyte, classical monocytes; ATI,

alveolar epithelial type 1 cells; ILC A, type A innate lymphoid cells; ATII, alveolar epithelial

type 2 cells; VE Venous, vascular endothelial venous cells; pDC, plasmacytoid dendritic cells.

Table 3: Cell type-specific differential gene expression in COPD and IPF lungs compared to control lungs

Cell type	Total genes in analysis	Number of upregulated genes in COPD	Number of downregulated genes in COPD	Number of upregulated genes in IPF	Number of downregulated genes in IPF
ATII	10964	272	2088	3886	2967
Alveolar Macrophage	5614	228	772	1847	1275
SMC	4265	40	183	1922	604
Fibroblast	3500	89	254	1268	658
ATI	3362	252	108	819	578
Myofibroblast	3099	120	399	1225	612
VE Capillary B	2446	54	338	412	943
B Plasma	2325	116	50	1039	460
VE Capillary A	2063	73	284	404	669
ILC A	2049	8	1	332	240
VE Venous	1310	33	114	230	374
Pericyte	1210	26	56	326	275
T Cytotoxic	1139	7	2	192	81

Associations were tested using limma [16] on variable genes only. Signficant association were adjusted to FDR 5%. Abbreviations: COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; ATII, alveolar epithelial type 2 cells; SMC, smooth muscle cells; ATI, alveolar epithelial type 1 cells; VE Capillary B, vascular endothelial - general capillary; VE Capillary A, vascular endothelial - aerocyte capillary; ILC A, type A innate lymphoid cells; VE Venous, vascular endothelial venous cells.

REFERENCES

[1]   Agustí A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. New England Journal of Medicine 2019;381:1248–56. https://doi.org/10.1056/nejmra1900475.

[2]   Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. New England Journal of Medicine 2018;378:1811–23. https://doi.org/10.1056/nejmra1705751.

[3]   Selman M, Martinez FJ, Pardo A. Why does an aging smoker's lung develop idiopathic pulmonary fibrosis and not chronic obstructive pulmonary disease? American Journal of Respiratory and Critical Care Medicine 2019;199:279–85. https://doi.org/10.1164/rccm.201806-1166pp.

[4]   Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 202050: a health-augmented macroeconomic modelling study. The Lancet Global Health 2023;11:e1183–93. https://doi.org/10.1016/s2214-109x(23)00217-6.

[5]   Wong AW, Koo J, Ryerson CJ, Sadatsafavi M, Chen W. A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies. BMC Pulmonary Medicine 2022;22. https://doi.org/10.1186/s12890-022-01922-2.

[6]   Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, et al. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nature Genetics 2019;51:494–505. https://doi.org/10.1038/s41588-018-0342-2.

[7]   Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Schwartz DA, Maher TM, et al.

Genome-wide association study across five cohorts identifies five novel loci associated with

idiopathic pulmonary fibrosis. Thorax 2022;77:829–33. https://doi.org/10.1136/thoraxjnl-2021-

218577.

[8]   Allen RJ, Guillen-Guio B, Oldham JM, Ma S-F, Dressen A, Paynton ML, et al. Genome-

wide association study of susceptibility to idiopathic pulmonary fibrosis. American Journal of

Respiratory and Critical Care Medicine 2020;201:564–74. https://doi.org/10.1164/rccm.201905-

1017oc.

[9]   Adams TS, Schupp JC, Poli S, Ayaub EA, Neumark N, Ahangari F, et al. Single-cell

RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary

fibrosis. Science Advances 2020;6. https://doi.org/10.1126/sciadv.aba1983.

[10]   Sauler M, McDonough JE, Adams TS, Kothapalli N, Barnthaler T, Werder RB, et al.

Characterization of the COPD alveolar niche using single-cell RNA sequencing. Nature

Communications 2022;13. https://doi.org/10.1038/s41467-022-28062-9.

[11]   Villaseñor-Altamirano AB, Jain D, Jeong Y, Menon JA, Kamiya M, Haider H, et al.

Activation of CD8[+] T cells in chronic obstructive pulmonary disease lung. American Journal of

Respiratory and Critical Care Medicine 2023;208:1177–95.

https://doi.org/10.1164/rccm.202305-0924oc.

[12]   Yang IV, Pedersen BS, Rabinovich E, Hennessy CE, Davidson EJ, Murphy E, et al.

Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis.

American Journal of Respiratory and Critical Care Medicine 2014;190:1263–72.

https://doi.org/10.1164/rccm.201408-1452oc.

[13]   Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al.

Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature

Biotechnology 2019;37:773–82. https://doi.org/10.1038/s41587-019-0114-2.

[14]   Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration

of cell subsets from tissue expression profiles. Nature Methods 2015;12:453–7.

https://doi.org/10.1038/nmeth.3337.

[15]   Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor

infiltrating immune cells with CIBERSORT, Springer New York; 2018, p. 243–59.

https://doi.org/10.1007/978-1-4939-7493-1_12.

[16]   Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential

expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research

2015;43:e47–7. https://doi.org/10.1093/nar/gkv007.

[17]   Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The

STRING database in 2023: proteinprotein association networks and functional enrichment

analyses for any sequenced genome of interest. Nucleic Acids Research 2022;51:D638–46.

https://doi.org/10.1093/nar/gkac1000.

[18]   Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A

Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis. Annals of

Internal Medicine 2012;156:684. https://doi.org/10.7326/0003-4819-156-10-201205150-00004.

[19]   Jin H, Liu Z. A benchmark for RNA-seq deconvolution analysis under dynamic testing

environments. Genome Biology 2021;22. https://doi.org/10.1186/s13059-021-02290-6.

[20]   Im Y, Kim Y. A comprehensive overview of RNA ceconvolution methods and their

application. Molecules and Cells 2023;46:99–105. https://doi.org/10.14348/molcells.2023.2178.

[21]   Bauer Y, White ES, Bernard S de, Cornelisse P, Leconte I, Morganti A, et al. MMP-7 is a

predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ

Open Research 2017;3:00074–2016. https://doi.org/10.1183/23120541.00074-2016.

[22]   Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the

pathogenesis of idiopathic pulmonary fibrosis. Respiratory Research 2016;17.

https://doi.org/10.1186/s12931-016-0343-6.

[23]   Zhang Y, Jiang M, Nouraie M, Roth MG, Tabib T, Winters S, et al. GDF15 is an

epithelial-derived biomarker of idiopathic pulmonary fibrosis. American Journal of Physiology-

Lung Cellular and Molecular Physiology 2019;317:L510–21.

https://doi.org/10.1152/ajplung.00062.2019.

[24]   Lagares D, Ghassemi-Kakroodi P, Tremblay C, Santos A, Probst CK, Franklin A, et al.

ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis.

Nature Medicine 2017;23:1405–15. https://doi.org/10.1038/nm.4419.

[25]   Schäfer M, Werner S. The cornified envelope: a first line of defense against reactive

oxygen species. Journal of Investigative Dermatology 2011;131:1409–11.

https://doi.org/10.1038/jid.2011.119.

[26]   Polverino F, Celli BR, Owen CA. COPD as an endothelial disorder: endothelial injury

linking lesions in the lungs and other organs? (2017 Grover Conference Series). Pulmonary

Circulation 2018;8:1–18. https://doi.org/10.1177/2045894018758528.

[27]   Kapellos TS, Bassler K, Aschenbrenner AC, Fujii W, Schultze JL. Dysregulated

functions of lung macrophage populations in COPD. Journal of Immunology Research

2018;2018:1–19. https://doi.org/10.1155/2018/2349045.

[28]   Tesfaigzi Y, Curtis JL, Petrache I, Polverino F, Kheradmand F, Adcock IM, et al. Does

chronic obstructive pulmonary disease originate from different cell types? American Journal of

Respiratory Cell and Molecular Biology 2023;69:500–7. https://doi.org/10.1165/rcmb.2023-

0175ps.

[29]   Freeman CM, Curtis JL. Lung dendritic cells: shaping immune responses throughout

chronic obstructive pulmonary disease progression. American Journal of Respiratory Cell and

Molecular Biology 2017;56:152–9. https://doi.org/10.1165/rcmb.2016-0272tr.

[30]   Dewhurst JA, Lea S, Hardaker E, Dungwa JV, Ravi AK, Singh D. Characterisation of

lung macrophage subpopulations in COPD patients and controls. Scientific Reports 2017;7.

https://doi.org/10.1038/s41598-017-07101-2.

[31]   Morrow JD, Chase RP, Parker MM, Glass K, Seo M, Divo M, et al. RNA-sequencing

across three matched tissues reveals shared and tissue-specific gene expression and pathway

signatures of COPD. Respiratory Research 2019;20. https://doi.org/10.1186/s12931-019-1032-z.

[32]   Huang Q, Wang Y, Zhang L, Qian W, Shen S, Wang J, et al. Single-cell transcriptomics

highlights immunological dysregulations of monocytes in the pathobiology of COPD.

Respiratory Research 2022;23. https://doi.org/10.1186/s12931-022-02293-2.

[33]   Ogger PP, Byrne AJ. Macrophage metabolic reprogramming during chronic lung disease.

Mucosal Immunology 2021;14:282–95. https://doi.org/10.1038/s41385-020-00356-5.

[34]   Fujii W, Kapellos TS, Baßler K, Händler K, Holsten L, Knoll R, et al. Alveolar

macrophage transcriptomic profiling in COPD shows major lipid metabolism changes. ERJ Open

Research 2021;7:00915–2020. https://doi.org/10.1183/23120541.00915-2020.

Figure 1. Boxplots showing cell type abundance score for each cell type split by disease status. Results are shown only for cell types detected in at least 10% of samples and whoe median proportion was greater than 1%. Statistical comparison was tested using linear regression adjusting for age, sex, ever smoking and total pack-year. * and † denote significant difference between COPD vs control and IPF vs control, respectively. Abbreviations: COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; ATI, alveolar epithelial type 1 cells; ATII, alveolar epithelial type 2 cells; cDC, classical dendritic cells; ILC, innate lymphoid cells; pDC, plasmacytoid dendritic cells; ncMonocyte, non-classical monocytesSMC; smooth muscle cells; VE Capillary A, vascular endothelial - aerocyte capillary; VE Capillary B, vascular endothelial - general capillary; VE Venous, venous vascular endothelial.

Figure 2. Venn diagrams showing the five cell types with the most cell type-specific gene expression levels associated with disease severity in COPD and IPF lungs. Genes associated with DLCO, FEV1, and FVC are colored blue, pink, and green, respectively. Cell-types with a higher number of gene expressions associated with disease severity are ordered left to right.

Figure 3. Protein-protein interaction network for the proteins encoded by genes in alveolar macrophages positively associated with COPD severity. Edges represent protein-protein associations based on association confidence score calculated using STRING database (version 12.0). The edge line thickness indicates the strength of data support. Disconnected nodes in the network were hidden for illustrative purpose.

Figure 4. Protein-protein interaction network for proteins encoded by genes in aberrant basaloid cells that were positively associated with IPF severity. Edges represent protein-protein associations based on association confidence score calculated using STRING database (version 12.0). The edge line thickness indicates the strength of data support. Disconnected nodes in the network were hidden for illustrative purpose.